An interesting subtext to these coronavirus driven times is the Battle of the Biotechs. The race for a vaccine or a treatment is justifiably generating a host of headlines as companies, big and small, vie to become the ones providing the much-needed solutions.Moderna (MRNA) has been attracting its share of attention with a potential vaccine. Shares of the messenger RNA specialist have come very far, very fast over the past four months and change. At the start of 2020, this was a $19 stock. Today, Moderna stock trades hands at roughly $52 — more than double its early 2020 price. So, what is all the excitement about?On Friday, Moderna announced it had been awarded $483 million from BARDA (the Biomedical Advanced Research and Development Authority)

Read More At Article Source | Article Attribution